by the end of 2022 you'll know if ACR was bought on mistake or not. By then there should/will be 10 dossiers with the FDA, and 3 product launches (currently only 1 ) as for breakout..... your more likely to catch Covid than witness a share price breakout with ACR. ACR's share price will not move until the generic products start delivering cash, and even then the returns need to be in the range of double digit % wise, to make this all worth while. The generics that we do have FDA approval for, 2 are small markets sales wise,,,,we really need Jublia (and who's our Jublia Partner?) the Amring Generic were partnered with, and the 6 generics with Trupharma were patnered with. Those 8 generics generate 100,s millions in sales each year. Jet
Add to My Watchlist
What is My Watchlist?
